CHA1

A proprietary combination of

EGCG and Decitabine

Pre-clinical efficacy at doses that are clinically attainable in humans

THE SCIENCE BEHIND

Mechanism defined in multiple pre-clinical experimental systems

Tumors reprogramed to re-express PDL1, decrease Wnt signaling, increase antigen presentation.

"Hot" tumor immune landscape with infiltrating CD8+ T cells and decreased

T reg cells